Maastricht UMC+

What Maastricht UMC+ does

Maastricht UMC+ is a public university medical center located in Maastricht, Netherlands, founded in 1986 as a collaboration between Maastricht University and the academic hospital. It operates as a government-funded, non-profit academic healthcare institution delivering tertiary and quaternary patient care alongside scientific research and medical education. With 5,001–10,000 employees, it serves as a regional referral center for Southeast Netherlands and operates the Maastricht UMC+ Comprehensive Cancer Center (MCCC), one of two Dutch institutions recognized by the Organisation of European Cancer Institutes (OECI) as a Comprehensive Cancer Center.

The organization's core digital product is MijnMUMC+, a patient portal built on Epic Systems' MyChart platform and accessible via web and mobile apps on iOS and Android. The portal provides patients access to electronic medical records, appointment management, video consultations through Microsoft Teams, secure messaging, and home monitoring, with integrations including DigiD for identity verification and Apple HealthKit/Google Fit for health data synchronization. Advanced clinical offerings include a long-read genome sequencing test for rare genetic disorders — developed with Radboud UMC, validated on 1,000 patients, and published in the New England Journal of Medicine — and a vocal biomarker–based smartphone application for COPD detection deployed in underserved Brazilian communities under the VOCAL project.

Revenue mechanics are governed by the Dutch regulated healthcare system: clinical services are reimbursed through mandatory health insurance, while academic functions (research, education, and complex care) are supported through direct government funding. The institution participates in multiple regional care networks, including OncoZON (coordinating oncology care across eight hospitals and the Maastro radiotherapy center) and ICUZON (nine hospitals collaborating on intensive care, with MUMC+ as coordinating center). Compliance posture includes ISO 27001, NEN 7510, GDPR, and WCAG 2.2 Level AA certifications.

Name

Maastricht UMC+

Legal name

Maastricht UMC+

Website

https://mumc.nl

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Maastricht UMC+ is a Dutch public university medical center delivering tertiary patient care, scientific research, and medical education. It operates the OECI-accredited Comprehensive Cancer Center, an Epic MyChart-based patient portal, and advanced diagnostics including NEJM-validated long-read genome sequencing.

Ownership category

akta.pro rank

Product category

Academic Medical Center Services

NAICS

General Medical and Surgical Hospitals (622110)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Medical Oncology (HLAKAFAB)

Keywords

• Academic hospital care
• Oncology treatment services
• Medical education training
• Clinical research services
• Rare disease diagnostics

Headquarters

HQ city

Maastricht

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Distribution channels3 records

Marketing channels4 records

Core offering

Maastricht UMC+ provides tertiary and quaternary clinical patient care, oncology treatment, and academic medical training and scientific research as a Dutch university medical center. It operates the OECI-accredited Comprehensive Cancer Center (MCCC), delivering multidisciplinary cancer care, advanced diagnostics including long-read genome sequencing for rare genetic disorders, and digital patient services through its MijnMUMC+ portal built on Epic's MyChart platform.

Product overview

Maastricht UMC+ is a Dutch university medical center offering healthcare services, scientific research, and medical education. Its primary digital product is MijnMUMC+, a patient portal built on Epic Systems' MyChart platform, available as both a web portal and mobile app (iOS/Android). The portal provides patients access to electronic medical records, appointments, test results, video consultations via Microsoft Teams, and secure messaging. MijnMUMC+ also integrates with Apple HealthKit and Google Fit for health data synchronization. The organization operates the Comprehensive Cancer Center (MCCC), an OECI-accredited cancer care center combining clinical care with research through the GROW institute. Advanced diagnostic services include a long-read genome sequencing test for rare genetic disorders (developed with Radboud UMC) and the VOCAL app using vocal biomarkers and machine learning for COPD detection in partnership with Brazilian universities.

Differentiator

Problem solved

Functional benefit

Brands

• Comprehensive Cancer Center: Maastricht UMC+ Comprehensive Cancer Center (MCCC) - a collaboration between Maastricht UMC+ Oncology Center and GROW – Research Institute for Oncology and Reproduction of Maastricht University. Recognized by OECI as a top cancer center.

Products and services

• MijnMUMC+ Patient Portal Digital patient portal providing access to electronic medical records, appointment scheduling, test results, video consultations, and secure messaging with healthcare providers. Available via web portal and mobile app (iOS and Android) for patients of Maastricht UMC+.
• Comprehensive Cancer Center (MCCC) Integrated cancer care center combining MUMC+ oncology patient care with the oncological research of the GROW research institute at Maastricht University. Provides multidisciplinary cancer treatment, scientific research, and education; OECI-accredited Comprehensive Cancer Center.
• Long-Read Genome Sequencing Test

Quantifiable outcome

• 3% increase in diagnostic yield for rare genetic disorders compared to standard diagnostics
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability6 records

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Radboud University Medical CentercoreStrategic or Co-development Partner · 13 June 2026Joint research partnership for development of long-read genome sequencing test for rare genetic disorders. Research validated in a study of 1,000 patients and published in New England Journal of Medicine.
• Federal University of Santa Catarina (Brazil)coreStrategic or Co-development Partner · 2 April 2024VOCAL project collaboration for deploying smartphone app using vocal biomarkers for COPD detection in underserved Brazilian communities, funded by UKRI.
• UFSCar (Brazil)coreStrategic or Co-development Partner · 2 April 2024VOCAL project collaboration for deploying smartphone app using vocal biomarkers for COPD detection in underserved Brazilian communities.
• ICUZON (Intensive Care Units Zuid-Oost Nederland)coreStrategic or Co-development Partner · 25 November 2023Network of nine Limburg and Brabant hospitals collaborating on intensive care. MUMC+ serves as the coordinating center. Organizes DICE Symposium for acute care nursing professionals.
• CIRO (Horn)minorOthersJoint operation of patient portal services (MijnMUMC+ and MijnCiro) under shared terms and conditions.
• Epic Systems CorporationcoreTechnology or IntegrationTechnology provider for MijnMUMC+ patient portal, developed in collaboration with Epic for electronic health records and patient engagement platform.
• GROW - Research Institute for Oncology and ReproductioncoreStrategic or Co-development PartnerResearch partnership between MUMC+ Oncology Center and GROW of Maastricht University Faculty of Health, Medicine and Life Sciences for integrated cancer research.
• OECI (Organisation of European Cancer Institutes)coreStrategic or Co-development PartnerEuropean cancer institute organization providing accreditation and network collaboration for comprehensive cancer center recognition.
• OncoZON (Oncologisch Netwerk Zuidoost-Nederland)coreChannel Partner/ Reseller/ DistributorRegional oncology network partnership with eight regional hospitals and Maastro radiotherapy center for coordinated cancer care delivery in Southeast Netherlands.
• MaastrocoreStrategic or Co-development PartnerRadiotherapy center partner within OncoZON network for comprehensive cancer treatment services.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Netherlands Cancer Institute (NKI): Specialized cancer research and treatment center in Amsterdam, also OECI-accredited. Closest Dutch peer specifically in oncology research and treatment, competing with MUMC+'s Comprehensive Cancer Center for clinical trials, oncology talent, and complex cancer cases.
• Amsterdam UMC: Merged academic medical center (AMC + VUmc) in Amsterdam, one of the largest UMCs in the Netherlands with strong oncology and research programs. Directly comparable peer competing for international patient referrals, research funding, and specialized oncology cases.
• Maastro Clinic: Dutch radiotherapy specialty clinic and OncoZON network partner of MUMC+ for comprehensive cancer treatment services. Closely comparable in oncology delivery within the Southeast Netherlands regional cancer care ecosystem.
• UMC Utrecht: Dutch university medical center providing tertiary care, research, and education across all major specialties including oncology. Directly comparable as a peer academic medical center in the Netherlands with similar three-pillar (care, research, education) mission and Epic-based digital infrastructure.
• Erasmus MC: Largest university medical center in the Netherlands, based in Rotterdam, offering comprehensive specialty care including a major oncology program. Directly comparable in mission and scale, competing with MUMC+ for research grants, complex patient referrals, and clinical talent.
• Radboud University Medical Center: Dutch university medical center in Nijmegen and direct research partner with MUMC+ on the long-read genome sequencing test. Comparable academic medical center with similar focus on rare disease diagnostics and translational research.
• Leiden University Medical Center (LUMC): Dutch university medical center in Leiden providing academic healthcare, research, and education across specialty care including oncology. Directly comparable as one of the seven Dutch UMCs operating under the same NFU (Netherlands Federation of University Medical Centres) framework.
• University Medical Center Groningen (UMCG): Northern Dutch university medical center providing tertiary care, research, and education. Directly comparable as one of the seven NFU Dutch UMCs with comparable academic mission, specialty oncology services, and research output.

Regional players

• University Hospitals Leuven (UZ Leuven): Belgian university hospital adjacent to the Netherlands and a major referral center for Southeast Netherlands patients. Comparable academic medical center providing tertiary and quaternary care, including oncology, to a regional catchment.

Broad incumbents

• Gustave Roussy Cancer Campus: Leading European comprehensive cancer center in France and OECI-accredited. Comparable as an internationally recognized European oncology center that competes with MUMC+ for international oncology referrals and research collaboration.

Market position

Strengths1 record

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/maastrichtumc
• Facebookfacebook.com/maastrichtumc
• LinkedInlinkedin.com/company/16971
• Instagraminstagram.com/mumc_maastricht

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maastricht UMC+